Fig. 7: BRD9 inhibition induces potent pro-apoptotic effects in primary CLL cells.

A Dose-response analysis of I-BRD9 treatment in 3 SF3B1^WT (SKL48, SKL152, SKL53) and 3 SF3B1^MUT (SKL147, SKL47, SKL157) primary CLL cell samples. The cell lines were treated with drug concentrations ranging from 0.001 to 50 µM for 2 days, and cell viability was determined by CellTiter-Glo 2.0. Dose-response curves are shown with 95% confidence intervals, while individual dots display the mean values of triplicates, with error bars representing the standard deviation. B Stacked density plots showing apoptosis assessment in the same primary CLL cell samples as in (A). Treatment with 5 µM Camptothecin and vehicle (DMSO) were used as the positive and negative controls, respectively. Apoptosis was evaluated by Annexin V/PI staining and subsequent flow cytometry analysis. The lower left (Annexin V-/PI- cells), upper left (Annexin V+/PI- cells), and upper right (Annexin V+/PI+ cells) quadrants in the density plots represent the percentages of viable, early apoptotic, and late apoptotic cells, respectively. C Stacked bar plot displaying differences in the percentages of viable, early apoptotic, and late apoptotic cells compared to negative controls with corresponding P values (Student’s t-test). The bar plot displays the mean values, with error bars representing the standard deviation. WT: wildtype; MUT: mutated; IC₅₀: half-maximal inhibitory concentration; RLU: relative luminescence unit.